Search Results
Oct 31, 2025, 03:00 ET Mycenax y RIN firman un acuerdo de licencia para impulsar el desarrollo de ADC
Biotech Inc. (TWO:4726), un CDMO de productos biológicos líder con sede en Taiwán, anunció la firma de un acuerdo de licencia con RIN Institute Inc. con sede en Japón, otorgando a Mycenax derechos para aplicar la tecnología de enlace Val-Leu-Lys (VLK) patentada de RIN en servicios CDMO en todo el mundo.
More news about: Mycenax Biotech Inc.
Oct 30, 2025, 23:46 ET Piramal Pharma Solutions formalizza la partnership stretta con IntoCell espandendo la propria piattaforma Payload-Linker e le capacità di sviluppo di bioconiugati
31 ottobre 2025 /PRNewswire/ -- Piramal Pharma Solutions, un'organizzazione di sviluppo e produzione su contratto (CDMO) leader mondiale nel settore e un'impresa di Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), ha siglato un memorandum d'intesa (MOU) per
More news about: Piramal Pharma Solutions
Oct 30, 2025, 19:00 ET Piramal Pharma Solutions formalisiert Partnerschaft mit IntoCell und erweitert seine Payload-Linker-Plattform und Biokonjugat-Kapazitäten
31. Oktober 2025 /PRNewswire/ -- Piramal Pharma Solutions, ein weltweit führendes Auftragsentwicklungs- und Produktionsunternehmen (CDMO) und Teil von Piramal Ltd. (NSE: PPLPHARMA) (BSE: 543635), hat eine Absichtserklärung (Memorandum of Understanding, MOU) unterzeichnet, um seine
More news about: Piramal Pharma Solutions
Oct 30, 2025, 18:56 ET Piramal Pharma Solutions officialise son partenariat avec IntoCell, élargissant ainsi sa plateforme de payload-linker et ses capacités en matière de bioconjugués
30 octobre 2025 /PRNewswire/ -- Piramal Pharma Solutions, une organisation de développement et de fabrication sous contrat (CDMO) de premier plan mondial, qui fait partie de Piramal Pharma Ltd. (NSE : PPLPHARMA) (BSE : 543635), a signé un protocole d'accord visant à renforcer
More news about: Piramal Pharma Solutions
Oct 30, 2025, 07:36 ET Piramal Pharma Solutions formaliza su asociación con IntoCell
30 de octubre de 2025 /PRNewswire/ -- Piramal Pharma Solutions, una organización líder mundial en desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), ha firmado un Memorando de Entendimiento (MOU) para consolidar su alianza estratégica
More news about: Piramal Pharma Solutions
Oct 30, 2025, 01:21 ET Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
Oct. 30, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has signed a Memorandum of Understanding (MOU) to solidify its strategic partnership
More news about: Piramal Pharma Solutions
Oct 30, 2025, 01:15 ET Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
Oct. 30, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has signed a Memorandum of Understanding (MOU) to solidify its
More news about: Piramal Pharma Solutions
Oct 29, 2025, 21:22 ET ロッテバイオロジクスとSKファームテコがADC CDMO強化に向けた戦略的パートナーシップを締結
View original content to download multimedia:https://www.prnewswire.com/jp/news-releases/skadc-cdmo-302599158.html SOURCE LOTTE BIOLOGICS
More news about: LOTTE BIOLOGICS
Oct 29, 2025, 10:33 ET Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced it has entered into a collaboration with
More news about: Cellipont Bioservices
Oct 29, 2025, 09:58 ET Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing
solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avecia, Inc. a leading contract development and manufacturing organization (CDMO) specializing in oligonucleotide therapeutics, today announced that they have entered into an evaluation agreement. Under the
More news about: Codexis
Oct 29, 2025, 09:00 ET Wheeler Bio Announces Strategic Partnership with Mitsubishi Corporation to Accelerate Asia-Pacific Business Development
Oct. 29, 2025 /PRNewswire/ -- Wheeler Bio, a U.S.-based High Science/High Touch contract development and biomanufacturing organization (CDMO), today announced a strategic partnership with Mitsubishi Corporation to expand Wheeler's commercial reach and business development activities across
More news about: Wheeler Bio, Inc.
Oct 29, 2025, 08:12 ET BioCina gibt Ernennung von Dr. Thomas Broudy zum Chief Executive Officer bekannt
BioCina zu leiten und unsere Mission, CDMO-Dienstleistungen von Weltklasse anzubieten, weiter voranzutreiben. Das talentierte Team, die wissenschaftliche Exzellenz und die Kundenorientierung von BioCina versetzen uns in die Lage, als vertrauenswürdiger globaler CDMO-Partner zu wachsen. Ich freue mich darauf,
More news about: BioCina
Oct 29, 2025, 05:01 ET IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea
GC Cell is a leading Korean biotechnology company focused on immune cell therapies, including CAR-NK, CAR-T, and CIK cell platforms, and CDMO services for cell and gene therapy. With extensive expertise in manufacturing and commercialization of autologous and allogeneic cell therapies, GC
More news about: IASO Bio
Oct 28, 2025, 10:00 ET TCI Biotech to Showcase Leadership as the "Liquid Expert" at SupplySide Global 2025, Featuring Clinically-Proven Innovations for Weight Management and Metabolic Health
About TCI Biotech TCI Biotech (TCI Co., Ltd.) is a global leader in CDMO+ services, specializing in the research, development, and manufacturing of health foods and cosmetics. Committed to innovation and scientific excellence,
More news about: TCI; TCI Biotech
Oct 28, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing
manner," said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. Andrea Conforto, S&M – VP CDMO Biotech, Olon S.p.A., added, "Together, we provide a seamless path from development to large-scale commercial manufacturing, setting new standards
More news about: Ajinomoto Bio-Pharma Services
Oct 28, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing
manner," said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. Andrea Conforto, S&M – VP CDMO Biotech, Olon S.p.A., added, "Together, we provide a seamless path from development to large-scale commercial manufacturing, setting new standards
More news about: Ajinomoto Bio-Pharma Services
Oct 28, 2025, 03:02 ET BioCina Announces Appointment of Dr. Thomas Broudy as Chief Executive Officer
"I am honored to lead BioCina and continue advancing our mission to deliver world-class CDMO services." Dr. Broudy brings over 20 years of experience in the biopharmaceutical and CDMO industries, spanning operations, business development, and strategic leadership. Prior to
More news about: BioCina
Oct 28, 2025, 03:02 ET BioCina Announces Appointment of Dr. Thomas Broudy as Chief Executive Officer
am honored to lead BioCina and continue advancing our mission to deliver world-class CDMO services. BioCina's talented team, scientific excellence, and client-centric focus position us to grow as a trusted global CDMO partner. I look forward to working closely with our employees, clients, and stakeholders
More news about: BioCina
Oct 28, 2025, 02:50 ET Samsung Biologics reports third quarter 2025 financial results
to separate the CDMO business from its subsidiary remains on track for completion in November 2025. This will enable each entity to maintain a clear strategic focus, allowing Samsung Biologics to enhance client satisfaction and long-term competitiveness as a dedicated, pure-play CDMO.
More news about: Samsung Biologics
Oct 27, 2025, 14:27 ET Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development
vendors and geographically dispersed sites, which adds substantial supply chain complexity and potential delays," said Alex Del Priore, Head - LM CDMO, Syngene International."By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in
More news about: Syngene International
Oct 27, 2025, 08:30 ET BioDlink Completes First International Shipment of Bevacizumab to Colombia
About BioDlink Biopharm Co., Ltd. BioDlink (1875.HK) is a leading global CDMO specializing in biologics and bioconjugates (ADCs/XDCs). Headquartered in Suzhou with centers in Shanghai and Beijing, the company provides fully integrated,
More news about: BioDlink Biopharm Co., Ltd.
Oct 27, 2025, 08:00 ET Simtra BioPharma Solutions expands global manufacturing footprint to advance the future of sterile injectables
Oct. 27, 2025 /PRNewswire/ -- Simtra BioPharma Solutions, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectables, is making progress on a dual-continent expansion strategy to meet growing global demand for complex, high-value
More news about: Simtra BioPharma Solutions
Oct 26, 2025, 03:53 ET WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
sustainable growth of our CRDMO business. Small molecule D&M service remains strong.The small molecule CDMO pipeline continued to expand. Q1-Q3 revenue of small molecule D&M services rose 14.1% year-over-year to RMB14.24 billion. In the first three quarters
More news about: WuXi AppTec
Oct 23, 2025, 07:30 ET Orion and Abzena Announce Exclusive Commercial License for Abzena's Antibody
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive focused commercial license to one of Abzena's monoclonal
More news about: Abzena
Oct 23, 2025, 07:00 ET ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at Children's National Hospital
About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support
More news about: Bio-Techne Corporation